Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
This 2011 review highlights the significant metabolic and cardiovascular risks associated with antipsychotic medications, particularly second-generation antipsychotics like clozapine and olanzapine. These drugs are linked to weight gain, hyperglycemia, dyslipidemia, and metabolic syndrome, increasing the risk of type 2 diabetes and cardiovascular disease. The exact mechanisms remain unclear but may
June 26, 2025
No Comments